FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Mylan Laboratories Limited, (Nashik FDF) Amlodipine and Valsartan Tablets Recall

Amlodipine and Valsartan Tablets, USP 5/160 mg, 30-count bottles, Rx Only, Made in Ind…

Mylan Laboratories Limited, (Nashik FDF) · Sinnar, Nashik District, N/A

Risk level
Class II
Reported by FDA
Dec 19, 2018
Recall ID
D-0320-2019
Check your lot numberHow we source this data

Summary

Mylan Laboratories Limited, (Nashik FDF) recalled Amlodipine and Valsartan Tablets starting Dec 4, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0320-2019 on Dec 19, 2018. Reason: GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. Status: Ongoing.

Why it was recalled

GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.

Product description

Amlodipine and Valsartan Tablets, USP 5/160 mg, 30-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. NDC 0378-1721-93.

Lot numbers, UPCs & expiration codes

Lot Numbers:3064084, 3069629, 3073148, 3073149,3076093, 3077772

Where it was sold

Product was distributed throughout the United States to several major distributors, including Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0320-2019
Classification
Class II
Status
Ongoing
Recall initiated
Dec 4, 2018
FDA report date
Dec 19, 2018
Quantity
141,995 HDPE bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Mylan Laboratories Limited, (Nashik FDF)

Original FDA data

Every field from FDA enforcement report D-0320-2019, exactly as published.

Show all FDA fields
City
Sinnar, Nashik District
Status
Ongoing
Country
India
Event ID
81707
Address
F-4 F-12, Malegaon M.I.D.C., Sinnar
Code information
Lot Numbers:3064084, 3069629, 3073148, 3073149,3076093, 3077772
Report date
Dec 19, 2018
Product type
Drugs
Recall number
D-0320-2019
Classification
Class II
Recalling firm
Mylan Laboratories Limited, (Nashik FDF)
Product quantity
141,995 HDPE bottles
Reason for recall
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Amlodipine and Valsartan Tablets, USP 5/160 mg, 30-count bottles, Rx Only, Made in India, Manufactured for: Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 U.S.A. NDC 0378-1721-93.
Distribution pattern
Product was distributed throughout the United States to several major distributors, including Puerto Rico.
Recall initiation date
Dec 4, 2018
Initial firm notification
Press Release
Center classification date
Dec 14, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0320-2019, published Dec 19, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls